Teknova

Avitide discovers, develops, manufactures and supplies custom and catalog biopharmaceutical affinity purification solutions to the biopharmaceutical industry. Avitide’s proprietary AVIPure™ affinity ligand portfolio sets the standard for precise affinity separations and consistent robust performance for its high-valued chromatographic products. Avitide develops these technologies with an industry-leading 3-month, concept to resin delivery service timeline that enables industry biopharmaceutical manufacturers and contract developers to achieve faster bioprocess development timelines, improved process economics, predictable scalability, and enable next-generation integrated continuous downstream processing. Avitide’s commercial resin manufacturing and supply operates under an ISO 9001:2015 quality management system and has been successfully audited for its quality systems and continuity of supply plan for its affinity chromatography products. Avitide has successfully deployed affinity purification technologies towards an array of biological molecules including enzymes, bispecific antibodies, therapeutic scaffolds, growth factors, hormones, insulins, blood factors, Fcfusions, cell-based therapies, vaccines, and gene therapy viral vectors. Avitide's management team brings substantial industry expertise and a successful track record in commercializing innovative biopharmaceutical manufacturing platforms. Avitide is financed by premier venture capital and private equity firms, including Polaris Venture Partners, OrbiMed Advisors, Mithril Capital Management, Sands
Capital Ventures, Section 32, SV Health Investors, Borealis Ventures, and NeoMed Management. For more information, visit www.avitide.com.

We are a biopharmaceutical company established in 1995 focused on developing products for the treatment of cancer and infectious diseases based on our proprietary Tarmogen ® platform. Tarmogens activate the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells, in contrast to traditional vaccines which predominately stimulate antibody production. We believe that our Tarmogen platform has applicability to a number of diseases, and may enable us to develop a broad portfolio of products. We have four Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications.

Tarmogens target the molecular profile that distinguishes a diseased cell from a normal cell. We have designed Tarmogens to target specific intracellular and extracellular proteins, or antigens, that play a role in oncology and infectious diseases which represent unmet medical needs. Collaborations with biopharmaceutical companies and research institutions have allowed us to advance the development of a number of our product candidates while managing our own research and development expenses relating to these product candidates.

We have two strategic collaborations with leading biotechnology companies. In October 2011, Gilead Sciences, Inc., exclusively licensed product candidates intended to treat chronic hepatitis B virus, or HBV, infection. Celgene Corporation entered into a collaboration and option agreement for certain oncology product candidates in May 2009. Under this agreement, in July 2013 Celgene exercised its option for a worldwide, exclusive license to the GI-6300 program, which is a Tarmogen program targeting the brachyury protein. Brachyury plays a role in the metastatic spread of certain cancers and is believed to be fundamental in the formation of chordomas, rare bone tumors of the spine. Through June 30, 2014, we have received over $60 million from these collaborations.

Lyophilization Technology, Inc. is a unique Technical Service and Contract Development and Manufacturing Organization. LTI provides comprehensive in-house capabilities ranging from thermal analysis, product design, formulation development, process engineering, streamlining operations, improving compliance, preclinical to Phase II clinical material preparation and technical support for a wide variety of products.

LTI has successfully developed formulations, manufacturing processes and prepared material for clinical trials for a wide variety of products.

• Anti-infectives
• Biologics / Vaccines
• Oncolytics / HPCs
• Small Molecules / Therapeutics

Development Services are conducted with product quality and a manufacturing mindset from the start, considering product administration, stability and processing requirements. Distinct processing areas are comprised of ISO 5 clean rooms directly linked to pilot-scale lyophilizers.

Clinical Manufacturing Area (CMA) is flexible for preparation of products with unique requirements, adheres to aggressive project timelines, and is fully cGMP compliant.
• Pre-clinical to Phase II Clinical Material
• Dedicated / disposable product contact items/equipment
• Combined aseptic processing with product containment
• Vials 2 to 100 mL and novel delivery systems
• US / EU complaint

Technical Services
The broad range of experience in a wide variety of products provides a specialized expertise from which you can capitalize.

Nanotherapeutics is a privately-held emerging biopharmaceutical company with both proprietary platform technologies and a diversified pipeline of products. The Company has expertise in pre-clinical and clinical development, formulation optimization, and cGMP manufacturing of biopharmaceutical products and medical devices. The Company's proprietary platform technologies can be used with all drug types, ranging from small molecules to proteins and vaccines.

Many of our diversified products have multiple indications ("dual-use"​) with potential in the areas of infectious diseases, CNS, oncology, vaccines, and biodefense. Over the past several years, we have focused our efforts on meeting the US government’s interests to develop safe, effective medical countermeasures against certain biological and radiological threats.

Protein Sciences (www.proteinsciences.com) is a biotechnology company that specializes in vaccine development and protein production. Our mission is our inspiration: to save lives and improve health by effectively responding to the changing world through the creation of innovative vaccines and biopharmaceuticals.

See where Flublok® Influenza vaccine is available at www.flublok.com.

We use our proprietary BEVS protein expression technology to produce high quality recombinant proteins quickly, reliably and at low cost. We have developed three main business lines that employ this technology:

1. Proprietary vaccines - we develop and produce the next generation of safer and more effective vaccines

2. GeneXpress® product development and manufacturing services - we partner with others to develop and manufacture modern vaccines, therapeutics and gene therapies

3. Research antigens - we offer a variety of high quality purified antigens and antibodies to the scientific community for disease research